Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
Cell intrinsic role of NF-κB-inducing kinase in regulating T cell-mediated immune and autoimmune responses.
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.
Animal assisted interventions in neurorehabilitation: A review of the most recent literature.
Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
B-50Alternate Scoring of the Paced Auditory Serial Addition Test (PASAT): Evaluating Strings of Consecutive Correct Responses as Predictors of Cognitive Functioning in Patients with Multiple Sclerosis.
Early phenotypic asymmetry of sister oligodendrocyte progenitor cells after mitosis and its modulation by aging and extrinsic factors.
[Case report: a case of chronic inflammatory demyelinating polyneuropathy (CIDP) exacerbated by influenza vaccination].
Age-specific sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg).
The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration.
The Symptom Inventory Disability-Specific Short Forms for Multiple Sclerosis: Construct Validity, Responsiveness, and Interpretation.
Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
Papaverine inhibits lipopolysaccharide-induced microglial activation by suppressing NF-κB signaling pathway.
Inhibition of Calcineurin Abrogates While Inhibition of mTOR Promotes Regulatory T Cell Expansion and Graft-Versus-Host Disease Protection by IL-2 in Allogeneic Bone Marrow Transplantation.
Cost of disorders of the brain in Spain.
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS)
ATX-MS-1467 in Multiple Sclerosis
Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS
Shape Analysis of the Corpus Callosum and Cerebellum in Female MS Patients with Different Clinical Phenotypes.
Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis.
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Targeting the shift from m1 to m2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil.
Fingolimod-Associated Peripheral Vascular Adverse Effects.
Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder.

Pages